Yeon Joo Lee, MD, MPH
Infectious Diseases Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Infections in Transplant Patients and Other Immunocompromised Patients
Request an Appointment
About Me
- Assistant Attending Physician
I am a physician with special expertise in the management of infections in patients with weakened immune systems.
Read more
My research interests focus on identifying the factors in these patients that predispose them to developing opportunistic viral infections after cancer treatment. I am also interested in studying the interactions between host, bacteria, virus, and gut microbiota. I am currently involved in various research projects including rapid identification of adenovirus types, investigation of risk factors for adenovirus infections, and gut microbiota in stem cell transplant recipients.
An infectious diseases specialist is a doctor with special training in diseases caused by microorganisms (bacteria, fungi, parasites, and viruses).
My Specialties
- Infections in Transplant Patients and Other Immunocompromised Patients
Education
- MD, Korea University College of Medicine
- MPH, UCLA School of Public Health
Residencies
- Korea University Medical Center
- Englewood Hospital and Medical Center (New Jersey)
Fellowships
- Memorial Sloan Kettering Cancer Center
Board Certifications
- Infectious Disease
- Internal Medicine
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, HMO
MSK has a tentative agreement with Cigna to continue coverage in 2024.
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Lee sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Co-Investigated by Dr. Lee
- A Study of Letermovir to Prevent a Recurrence of Cytomegalovirus Infection
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Lee YJ, Glezerman IG, Tamari R, et al. BK polyoma virus nephropathy in hematopoietic cell transplant recipients. Journal of Onco-Nephrology. 2019;3(3):113-123. doi:10.1177/2399369319858362.
Chan SY, Prockop SE, Boulad F, Papanicolaou GA, Lee YJ. Rapid Virologic Response to Brincidofovir in Children with Disseminated Adenovirus Infection. Infect Chemother. 2021 Sep;53(3):572-577. doi: 10.3947/ic.2020.0204. Epub 2020 Aug 10. PMID: 32869551; PMCID: PMC8511378.
Stern A, Su Y, Lee YJ, Seo S, Shaffer B, Tamari R, Gyurkocza B, Barker J, Bogler Y, Giralt S, Perales MA, Papanicolaou GA. A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 Jun;26(6):1195-1202. doi: 10.1016/j.bbmt.2020.02.009. Epub 2020 Feb 20. PMID: 32088367; PMCID: PMC8210627.
Read more
Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, Bogler Y, Caldararo M, Figueroa CJ, Glickman MS, Joanow A, Kaltsas A, Lee YJ, Lucca A, Mariano A, Morjaria S, Nawar T, Papanicolaou GA, Predmore J, Redelman-Sidi G, Schmidt E, Seo SK, Sepkowitz K, Shah MK, Wolchok JD, Hohl TM, Taur Y, Kamboj M. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020 Aug;26(8):1218-1223. doi: 10.1038/s41591-020-0979-0. Epub 2020 Jun 24. PMID: 32581323; PMCID: PMC7785283.
Shah GL, DeWolf S, Lee YJ, Tamari R, Dahi PB, Lavery JA, Ruiz J, Devlin SM, Cho C, Peled JU, Politikos I, Scordo M, Babady NE, Jain T, Vardhana S, Daniyan A, Sauter CS, Barker JN, Giralt SA, Goss C, Maslak P, Hohl TM, Kamboj M, Ramanathan L, van den Brink MR, Papadopoulos E, Papanicolaou G, Perales MA. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020 Dec 1;130(12):6656-6667. doi: 10.1172/JCI141777. PMID: 32897885; PMCID: PMC7685738.
Lee YJ, Fang J, Zavras PD, Prockop SE, Boulad F, Tamari R, Perales MA, Papadopoulos EB, Jakubowski AA, Giralt SA, Papanicolaou GA. Adenovirus Viral Kinetics and Mortality in Ex Vivo T Cell-Depleted Hematopoietic Cell Transplant Recipients With Adenovirus Infection From a Single Center. J Infect Dis. 2020 Sep 1;222(7):1180-1187. doi: 10.1093/infdis/jiaa237. PMID: 32374872; PMCID: PMC7459134.
Bogler Y, Stern A, Su Y, Lee YJ, Seo SK, Shaffer B, Perales MA, Papanicolaou GA, Neofytos D. Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. Med Mycol. 2021 Oct 4;59(10):970-979. doi: 10.1093/mmy/myab025. PMID: 34036319; PMCID: PMC8487767.
Lee YJ, Su Y, Cho C, Tamari R, Perales MA, Jakubowski AA, Papanicolaou GA. Human Herpesvirus 6 DNAemia Is Associated With Worse Survival After Ex Vivo T-Cell-Depleted Hematopoietic Cell Transplant. J Infect Dis. 2022 Feb 1;225(3):453-464. doi: 10.1093/infdis/jiab412. PMID: 34390240; PMCID: PMC8807153.
Caldararo M, Algazaq J, Schmidt E, Joanow A, Mariano A, Predmore J, Politikos I, Cho C, Stein EM, Wen X, Travis WD, Raible K, Cintron M, Babady NE, Papanicolaou G, Lee YJ. Atypical pathogens presenting with pulmonary consolidations detected by cell-free DNA next-generation sequencing in patients with hematologic malignancies. Infect Dis Clin Pract (Baltim Md). 2022 Mar;30(2):e1101. doi: 10.1097/ipc.0000000000001101. PMID: 35586753; PMCID: PMC9109825.
Gali V, Kaltsas A, Cintrón M, Papanicolaou GA, Lee YJ. Concurrent pulmonary Aspergillus and non-Aspergillus mold infections in allogeneic hematopoetic cell transplant recipients. Transpl Immunol. 2023 Feb;76:101745. doi: 10.1016/j.trim.2022.101745. Epub 2022 Nov 12. PMID: 36379375; PMCID: PMC9839572.
Visit PubMed for a full listing of Dr. Lee’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Yeon Joo Lee discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].